GLP-1 Peptide Atlas, by Delfa

TerminatedPhase 4Results posted

Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure

Treatment With Glucagon-Like Peptide-1 Receptor, Exenatide, in Patients With Diabetes and Heart Failure With Normal Left Ventricular Ejection Fraction

Lead sponsor

Baylor College of Medicine

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Heart failure, Type 2 diabetes

Key I/E criterion

—

Primary endpoint

•Aortic Stiffness

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00799435

Org study ID613

Secondary ID1K01HL092585

Secondary ID1K01HL092585-01

Secondary IDH-22906Baylor College of Medicine

Timeline

Milestones

Study first posted2008-11-27estimated

Results first posted2017-09-21actual

Last update posted2020-09-04actual

Study start2009-07 (month precision)

Primary completion2012-04actual (month precision)

Study completion2012-04actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Heart failureType 2 diabetes

Eligibility

Who can enroll

Minimum age30 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Stable New York Heart Association (NYHA) Class II-IV heart failure symptoms for at least 4 weeks before study entry

•Diagnosis of diastolic heart failure with a normal ejection fraction

•Admitted to the hospital with a diagnosis of heart failure in the 12 months before study entry

•Type 2 diabetes

Exclusion criteria

•Unstable angina, heart attack, coronary artery bypass surgery, or angioplasty in the 3 months before study entry

•Angina with exertion

•Technically inadequate echocardiogram

•Atrial fibrillation or atrial flutter

•Severe valvular heart disease

•Significant kidney insufficiency (serum creatinine greater than 2.0 mg/dL or require hemodialysis)

•Conditions that may be associated with changes in markers of fibrosis or collagen turnover (e.g., ongoing or active rheumatological disease, requiring significant anti-inflammatory agents, immunosuppression, pulmonary fibrosis, active cancer)

•Significant history of active substance abuse

•Type 1 diabetes

•Type 2 diabetes requiring chronic insulin use before study entry

•Active thiazolidinedione (TZD) use, because TZDs have been shown to worsen volume retention and may exacerbate signs and/or symptoms of heart failure

•Pregnant or breastfeeding

•Hypertrophic cardiomyopathy

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers

Other (unclassified)

Cardiometabolic biomarkers

1 endpoint

Primary/protocol endpoint

Change in Aortic Stiffness, as Measured by the Change in the Mean Aortic Pulse Wave Velocity

Time frame:Measured at Week 12

change from baseline, improvement

Posted result

Group	Value (mean), m/sec	95% CI
Usual CareBaseline Pulse Wave Velocity	11.4	—
Follow-up Pulse Wave Velocity	NA	—
ExenatideBaseline Pulse Wave Velocity	9.3	—
Follow-up Pulse Wave Velocity	10.2	—

Other (unclassified)

1 endpoint

Secondary/protocol endpoint/low confidence

Changes in Left Ventricular Diastolic Stiffness, Serum Levels of Advanced Glycation End Products, Serum Biomarkers of Collagen Synthesis, and Serum Levels of Brain Natriuretic Peptide

Time frame:Measured at Week 12

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.